Clinical Trial Update: Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous CINRYZE with recombinant human hyaluronidase for prevention of angioedema attacks in hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Cinryze (C1 esterase inhibitor)
• Recombinant human hyaluronidase (recombinant human hyaluronidase (rHuPH20))

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 2 | Status: COMPLETED | Results posted: 2015-06-12